NEW YORK (GenomeWeb News) – Provista Diagnostics said today that it has licensed biomarker technologies developed by researchers at Arizona State University's Biodesign Institute.
The company will evaluate the technologies for use in the early detection of breast cancer, ovarian cancer, and human papillomavirus.
The licensed technologies were developed primarily in the labs of Biodesign Institute researchers Joshua LaBaer and Karen Anderson, both of whom work extensively with protein microarrays. LaBaer and Anderson are both members of Provista's scientific advisory board.
"With the advent of molecularly-targeted therapeutics, biomarkers that are associated with biological subtypes of cancer may be useful for predicting responses to therapeutic interventions," LaBaer, director of the Virginia G. Piper Center for Personalized Diagnostics at the Biodesign Institute at ASU, said in a statement. "If we can significantly advance the early detection of these cancers, we can save thousands of lives each year."
Financial and other terms of the agreement were not disclosed.